Your browser doesn't support javascript.
loading
Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy.
Figlioli, Gisella; De Nicolo, Arcangela; Catucci, Irene; Manoukian, Siranoush; Peissel, Bernard; Azzollini, Jacopo; Beltrami, Benedetta; Bonanni, Bernardo; Calvello, Mariarosaria; Bondavalli, Davide; Pasini, Barbara; Vignolo Lutati, Francesca; Ogliara, Paola; Zuradelli, Monica; Pensotti, Valeria; De Vecchi, Giovanna; Volorio, Sara; Verderio, Paolo; Pizzamiglio, Sara; Matullo, Giuseppe; Aneli, Serena; Birolo, Giovanni; Zanardi, Federica; Tondini, Carlo; Zambelli, Alberto; Livraghi, Luca; Franchi, Michela; Radice, Paolo; Peterlongo, Paolo.
Afiliação
  • Figlioli G; Genome Diagnostics Program, IFOM, FIRC Institute for Molecular Oncology, 20139 Milan, Italy.
  • De Nicolo A; Cancer Genomics Program, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
  • Catucci I; Genome Diagnostics Program, IFOM, FIRC Institute for Molecular Oncology, 20139 Milan, Italy.
  • Manoukian S; Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
  • Peissel B; Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
  • Azzollini J; Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
  • Beltrami B; Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
  • Bonanni B; Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
  • Calvello M; Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
  • Bondavalli D; Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
  • Pasini B; Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
  • Vignolo Lutati F; Medical Genetics Unit, University Hospital Città della Salute e della Scienza di Torino, 10126 Turin, Italy.
  • Ogliara P; Medical Genetics Unit, University Hospital Città della Salute e della Scienza di Torino, 10126 Turin, Italy.
  • Zuradelli M; Medical Genetics Unit, University Hospital Città della Salute e della Scienza di Torino, 10126 Turin, Italy.
  • Pensotti V; Department of Oncology, IRCCS Humanitas Research Hospital, via Manzoni 56, Rozzano, 20089 Milan, Italy.
  • De Vecchi G; Cancer Genetic Test Laboratory, Cogentech srl Società Benefit a Socio Unico, 20139 Milan, Italy.
  • Volorio S; Cancer Genetic Test Laboratory, Cogentech srl Società Benefit a Socio Unico, 20139 Milan, Italy.
  • Verderio P; Cancer Genetic Test Laboratory, Cogentech srl Società Benefit a Socio Unico, 20139 Milan, Italy.
  • Pizzamiglio S; Unit of Bioinformatics and Biostatistics, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
  • Matullo G; Unit of Bioinformatics and Biostatistics, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
  • Aneli S; Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
  • Birolo G; Medical Genetics Unit, University Hospital Città della Salute e della Scienza di Torino, 10126 Turin, Italy.
  • Zanardi F; Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
  • Tondini C; Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
  • Zambelli A; Bioinformatics Core Unit, IFOM, FIRC Institute of Molecular Oncology, 20139 Milan, Italy.
  • Livraghi L; Medical Oncology Unit, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy.
  • Franchi M; Medical Oncology Unit, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy.
  • Radice P; Medical Oncology Unit, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy.
  • Peterlongo P; Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.
Cancers (Basel) ; 13(3)2021 Jan 30.
Article em En | MEDLINE | ID: mdl-33573335
Germline pathogenic variants (PVs) in the BRCA1 or BRCA2 genes cause high breast cancer risk. Recurrent or founder PVs have been described worldwide including some in the Bergamo province in Northern Italy. The aim of this study was to compare the BRCA1/2 PV spectra of the Bergamo and of the general Italian populations. We retrospectively identified at five Italian centers 1019 BRCA1/2 PVs carrier individuals affected with breast cancer and representative of the heterogeneous national population. Each individual was assigned to the Bergamo or non-Bergamo cohort based on self-reported birthplace. Our data indicate that the Bergamo BRCA1/2 PV spectrum shows less heterogeneity with fewer different variants and an average higher frequency compared to that of the rest of Italy. Consistently, four PVs explained about 60% of all carriers. The majority of the Bergamo PVs originated locally with only two PVs clearly imported. The Bergamo BRCA1/2 PV spectrum appears to be private. Hence, the Bergamo population would be ideal to study the disease risk associated with local PVs in breast cancer and other disease-causing genes. Finally, our data suggest that the Bergamo population is a genetic isolate and further analyses are warranted to prove this notion.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article